By ONN Staff
Articles
Oncology Nursing News Top Stories: October 2022
October 31, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from October 2022.
Oncology Nursing News Top Stories: September 2022
September 29, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from September 2022.
ODAC Committee Votes Against Upholding 3 Indications in Lung and Hematologic Malignancies
September 26, 2022
Article
On September 22 and 23, 2022, the FDA’s Oncologic Drugs Advisory Committee (ODAC) convened for a hearing to assess the risk-benefit ratio of 3 agents.
Oncology Nursing News Top Stories: August 2022
August 31, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2022.
Evolution of DLBCL Treatment Options Render ASCT Unsuitable for Many Patients
July 30, 2022
Article
In the modern era, the number of patients with diffuse large B-cell lymphoma who will derive benefit from autologous stem cell transplantation is small, according to Jeremy S. Abramson, MD, MMSc.
Oncology Nursing News Top Stories: July 2022
July 29, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from July 2022.
Addition of Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression, Death in DLBCL
July 23, 2022
Article
Phase 3 findings from the POLARIX trial showed that the addition of platuzumab vedotin to rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a 27% reduction in risk of disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.
Ixazomib/Lenalidomide/Dexamethasone Shows Consistent Outcomes in 3 Real-World Analyses of Use for Patients with R/R Multiple Myeloma
July 21, 2022
Article
A combined analysis of 3 real-world studies assessing the use of ixazomib/lenalidomide/dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma found the patient outcomes to be consistent with original phase 3 findings.
Zanubrutinib Significantly Improves PFS in Treatment-Naïve CLL/SLL Across Various High-Risk Subsets
July 21, 2022
Article
Patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, achieved superior progression-free survival with zanubrutinib vs a combination of bendamustine plus rituximab.
Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance
April 21, 2022
Article
PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.